Summary of Interim Report July - September 2024
| (SEK) | |||||
| Group Overview | 2024-07-01 | 2023-07-01 | 2024-01-01 | 2023-01-01 | |
| 2024-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | ||
| 3 month | 3 month | 9 month | 9 month | ||
| Operating income | 4 650 | 878 | 45 030 | 104 835 | |
| Profit/loss after financial items | -9 914 833 | -8 016 849 | -24 021 221 | -15 081 319 | |
| Balance Sheet total assets | 92 709 939 | 150 142 414 | 92 709 939 | 150 142 414 | |
| Equity / Assets ratio | 84% | 90% | 84% | 90% | |
| Earnings per share | -0,05 | -0.08 | -0,12 | -0.16 | |
| Number of shares | 206 815 258 | 96 994 446 | 206 815 258 | 96 994 446 | |
| Earnings per share after dilution* | -0.04 | -0.06 | -0.10 | -0.11 | |
| Parent Company Overview | 2024-07-01 | 2023-07-01 | 2024-01-01 | 2023-01-01 | |
| 2024-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | ||
| 3 month | 3 month | 9 month | 9 month | ||
| Operating income | 4 650 | 878 | 45 030 | 104 835 | |
| Profit/loss after financial items | -5 903 757 | -8 064 889 | -19 826 199 | -14 813 578 | |
| Balance Sheet total assets | 96 750 454 | 148 435 929 | 96 750 454 | 148 435 929 | |
| Equity / Assets ratio | 85% | 92% | 85% | 92% | |
| Earnings per share | -0,03 | -0.08 | -0,10 | -0.15 | |
| Number of shares | 206 815 258 | 96 994 446 | 206 815 258 | 96 994 446 | |
| Earnings per share after dilution* | -0.02 | -0.06 | -0.08 | -0.11 |
* Upon full exercise of all options in TO2, TO3 and Option Program 2022/2027.
Revenue and Result
Scandinavian Real Heart AB is working with research and development and currently has no sales of any products. The income reported for the period consists mainly of received de minimis grants. Research and development costs of Realheart® TAH were capitalized during Q4 with 5.7 MSEK. During the period, capitalized research and development costs were written down by 6.3 MSEK.
Employees
The number of employees in the Group at the end of the quarter was 11 full-time employees.
Related Party Transactions
No significant related party transactions have taken place during the period.
Significant Risks and Uncertainties
Realheart's focus is on getting through the pre-clinical phase (Hemolysis, GLP studies on animals and endurance tests) to be able to start clinical studies. This means that the company must finalize the version of both the controller and the heart pump that will be included in these tests. Realheart must also conduct parallel discussions with the Notified Body in the EU and with the FDA in the US to ensure the fastest and safest route to market for the product. The company is continuously working on measures to minimize delays. Furthermore, the continued product development requires that the company can solve its financing. The board is continuously working with different scenarios to ensure the company's future operations.
Financial Position
At the end of the period, the Group's cash and cash equivalents amounted to 31.7 MSEK. At present, the Group does not generate its own positive cash flow and is thus dependent on external financing. In order to solve the longer-term financing needs, the Board of Directors is continuously evaluating options for further capitalization of the company.
CEO Comment
During the third quarter, we have taken further steps in the preclinical validation of Realheart® TAH. As a result of the high innovation standard in our device, we have successfully established new important collaborations with the University of Gothenburg and the Hannover Medical School. These collaborations aim to accelerate the preclinical testing of Realheart® TAH, as well as familiarize leading transplantation surgeons with the device ahead of clinical studies. Further, we have proudly announced positive results from three separate studies reaffirming the promising hematological profile as well as the physiological control functions of Realheart® TAH. In parallel, our ongoing activities to optimize the preclinical safety study protocol are moving ahead. Collectively, our step-wise successes reflect the company's work in moving toward the clinical evaluation of our artificial heart.
Significant Events During the Third Quarter of the Year
At the beginning of the period, the outcome of the Company's rights issue is published. The outcome shows that 38,083,456 units were subscribed for with unit rights, corresponding to approximately 39.3 percent of the Rights Issue. In addition, the Company has received subscription applications for 5,527,237 units, corresponding to approximately 5.7 percent of the Rights Issue, for subscription without unit rights. Through the Rights Issue, the Company will initially receive approximately SEK 24.3 million before issue costs.
Halfway into July, Realheat carries out a directed issue of units to guarantors in connection with the completed rights issue. The Company's Board of Directors, based on the authorization from the Annual General Meeting on June 7, 2024, has decided to issue 6,300,000 units as guarantee compensation directed to a number of the guarantors who provided guarantee commitments in the rights issue of units carried out by the Company during the period June 12 through July 5, 2024, in accordance with the guarantee agreements entered into. Through the directed issue to the underwriters, 6,300,000 warrants of series TO3 are also issued, which entitle to subscribe for a maximum of 3,150,000 shares in the Company. Upon full exercise of the Warrants, the share capital will increase by a maximum of SEK 126,000.00.
July ends with Realheart announcing the last day of trading in BTUs and the first day of trading in warrants of series TO3. The number of warrants of series TO3 amounts to 54,910,406. Upon full exercise of all warrants of series TO3, the Company can be provided with a maximum of 27,455,203 new shares, which corresponds to a dilution of 11.7 percent.
During the first half of August, the Company announces the appointment of Jimmy Nybom as new interim CFO, during the ongoing recruitment process of a permanent CFO. Jimmy has had extensive contacts with Realheart as the company's auditor during the years 2019-2022 and is therefore well versed in the company's finances and operations.
In the second half of August, Realheart announces that it has entered into a collaboration with a leading veterinary large animal unit at the University of Gothenburg in Sweden for the continued preclinical safety evaluation of the Realheart® TAH artificial heart. The purpose is to conduct high-quality animal experimental large animal experiments required to ultimately conduct a clinical study. This will also facilitate the preparation of the clinical trial planned to be conducted in Sweden.
The final event of the period is an announcement that the company will present new data from two successful preclinical studies evaluating the treatment safety of the company's total artificial heart Realheart® TAH, at the 30th Annual Meeting of the International Society for Mechanical Circulatory Support (ISMCS) 2024, on November 13-15 in Utsunomiya, Japan.
Significant Events After the End of the Period
The first event after the end of the period is an announcement that the Company has published a preclinical study describing a new method to simulate hemolysis in artificial hearts using pumping mechanisms. This unique method will be important in the further development of Realheart® TAH. Based on its innovative approach, the study was awarded the ESAO-SAGE research prize at the 50th Congress of the European Society for Artificial Organs 2024.
Closer to mid-October, the company announces a collaboration with Professors Arjang Ruhparwar and Jan Schmitto, at the Department of Cardiothoracic, Transplantation and Vascular Surgery at Hannover Medical School, Hannover, Germany. The collaboration aims to familiarize leading transplant surgeons with Realheart® TAH and gain valuable professional input for the clinical trials. Realheart® TAH is intended for use in patients awaiting heart transplantation or as an alternative to transplantation.
November begins with the publication of the communiqué from Realheart's extraordinary general meeting. At the same time, the record date for the reverse share split in the Company is announced as November 22. The reverse share split will take place according to the ratio 1:100, whereby one hundred (100) existing shares will be consolidated into one (1) share.
For more information, please contact:
Ina Laura Perkins, CEO
Phone: +46 (0) 70 406 49 21
E-mail: inalaura.perkins@realheart.se
Certified Adviser: Svensk Kapitalmarknadsgranskning AB, www.skmg.se
About Us
Scandinavian Real Heart AB (publ) is developing the first artificial heart that mimics the shape, function, and blood flow pattern of the human heart. These unique product features provide completely new opportunities to save lives and give patients a good quality of life while waiting for a heart transplant. Realheart® TAH (Total Artificial Heart) is now being evaluated in extensive preclinical trial models ahead of a first clinical study in patients. In the future, artificial hearts may also become an alternative to transplantation for broader groups of patients with severe heart failure. The company's shares are traded on Nasdaq Stockholm First North Growth Market. For more information, visit www.realheart.se
This information is information that Scandinavian Real Heart is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-11-14 08:00 CET.
